Article Information
History
- March 22, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Rebecca Elyanow1,*,#,
- Thomas M. Snyder1,*,
- Sudeb C. Dalai1,2,
- Rachel M. Gittelman1,
- Jim Boonyaratanakornkit3,4,
- Anna Wald3,4,5,6,
- Stacy Selke6,
- Mark H. Wener5,6,
- Chihiro Morishima6,
- Alex L. Greninger6,
- Michael R. Holbrook7,
- Ian M. Kaplan1,
- H. Jabran Zahid8,
- Jonathan M. Carlson8,
- Lance Baldo1,
- Thomas Manley1,
- Harlan S. Robins1 and
- David M. Koelle3,4,6,9,10
- 1Adaptive Biotechnologies, Seattle, Washington, USA
- 2Stanford University School of Medicine, Stanford, California, USA
- 3Department of Medicine, University of Washington, Seattle, Washington, USA
- 4Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
- 5Department of Epidemiology, University of Washington, Seattle, Washington, USA
- 6Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA
- 7National Institute of Allergy and Infectious Diseases Integrated Research Facility, Frederick, Maryland, USA
- 8Microsoft Research, Redmond, Washington, USA
- 9Department of Global Health, University of Washington, Seattle, Washington, USA
- 10Benaroya Research Institute, Seattle, Washington, USA
- ↵#Corresponding author: Rebecca Elyanow, PhD Adaptive Biotechnologies 1551 Eastlake Ave. E. Seattle, Washington, 98102, relyanow{at}adaptivebiotech.com
↵* These authors contributed equally.
Posted March 22, 2021.
T-cell receptor sequencing identifies prior SARS-CoV-2 infection and correlates with neutralizing antibody titers and disease severity
